Japan PPI inflation slips to 11-mth low in July
Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company with a market capitalization of $7.09 billion, has sold 3,294 shares of the company’s common stock. The transaction, which took place on March 17, was executed at an average price of $39.04 per share, amounting to a total value of approximately $128,598. Following this sale, Kelsey retains ownership of 293,051 shares, which includes 104,850 restricted stock units. This transaction was carried out under a Rule 10b5-1 plan, initially adopted to cover tax obligations related to the vesting of restricted stock units. According to InvestingPro data, RVMD maintains strong liquidity with a current ratio of 14.2, and holds more cash than debt on its balance sheet. While five analysts have recently revised earnings downward, detailed financial analysis and additional insights are available in the comprehensive Pro Research Report, covering over 1,400 US stocks.
In other recent news, Revolution Medicines reported a net loss of $194.6 million for the fourth quarter of 2024, an increase from $161.5 million in the same quarter of the previous year. Despite the increased losses, the company maintains a robust cash position, ending the year with $2.3 billion in cash and investments, supported by $823 million from an equity offering. Revolution Medicines has announced guidance for a projected net loss between $840 million and $900 million for 2025, reflecting increased expenses related to clinical development programs. Analysts from H.C. Wainwright have raised the company’s stock target to $73 while maintaining a Buy rating, citing the company’s strong balance sheet and expected data catalysts. Meanwhile, Needham analysts have lowered their price target to $59, also maintaining a Buy rating, following the company’s fourth-quarter earnings report. Revolution Medicines is advancing two additional registrational trials for its investigational drug daraxonrasib, targeting earlier lines of pancreatic ductal adenocarcinoma (PDAC), with trials set to begin in the second half of 2025. Investors are also advised to monitor upcoming clinical data on zoldonrasib (RMC-9805), expected in mid-2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.